Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
173 hedge funds and large institutions have $249M invested in Revance Therapeutics, Inc. in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 60 increasing their positions, 50 reducing their positions, and 59 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
20% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 50
13% less call options, than puts
Call options by funds: $15M | Put options by funds: $17.3M
14% less funds holding
Funds holding: 201 → 173 (-28)
42% less capital invested
Capital invested by funds: $430M → $249M (-$181M)
46% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 59
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$25.9M |
| 2 |
OBAM
ODDO BHF Asset Management
Paris,
France
|
+$19.1M |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$8.49M |
| 4 |
NM
Newtyn Management
New York
|
+$7.88M |
| 5 |
Millennium Management
New York
|
+$6.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$15.8M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$13M |
| 3 |
KC
Kryger Capital
London,
United Kingdom
|
-$8.65M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$8.37M |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$8.26M |
RVNC Hedge Fund Activity: Q4 2024 in Review
173 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2024, worth a combined $249M — down 42% from $430M a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of RVNC and 32 opened new positions — a net loss of 27 holders — while 50 trimmed existing stakes and 60 added.
The largest buyer was Beryl Capital Management, opening a new position worth an estimated $25.9M. The largest seller was Franklin Resources, cutting an estimated $15.8M.
- 173 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2024, down from 201 in Q3 2024.
- Funds reported $249M of Revance Therapeutics, Inc. stock for Q4 2024, down 42% quarter-over-quarter.
- 32 funds opened new Revance Therapeutics, Inc. positions in Q4 2024 and 59 closed out, a net change of -27 holders.
- The largest Revance Therapeutics, Inc. buyer in Q4 2024 was Beryl Capital Management, an estimated $25.9M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2024 was Franklin Resources, an estimated $15.8M sold.
Based on aggregated 13F filings for Q4 2024.